CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akanda Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akanda Corp
1a, 1b Learoyd Road
Phone: +44 2034889514p:+44 2034889514 NEW ROMNEY, ON  TN28 8XU  United Kingdom Ticker: AKANAKAN
On 5/3/2024, the Securities and Exchange Commission (SEC) charged BF Borgers CPA PC and its owner, Benjamin F. Borgers, with significant violations of Public Company Accounting Oversight Board (PCAOB) standards across more than 1,500 SEC filings from January 2021 to June 2023. The charges included falsely representing compliance with PCAOB standards to clients, fabricating audit documentation, and inaccurately stating compliance in audit reports. According to the SEC's order, of 369 BF Borgers' clients whose public filings from January 2021 through June 2023 incorporated the firm's audits and reviews, at least 75 percent of the filings incorporated audits and reviews that did not comply with PCAOB standards. The financials in this report may include past audits and reviews conducted by BF Borgers CPA PC that are deemed not compliant with PCAOB standards.
Business Summary
Akanda Corp. is an international medical cannabis and wellness platform company. The Company’s portfolio includes Canmart Ltd. (CanMart), a United Kingdom-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the United Kingdom. Canmart is a licensed importer and distributor of CBD Extraction for Medicinal Purposes (CBPMs) in the United Kingdom. CanMart holds a controlled drug license issued by the Home Office to possess and supply CBPMs in the United Kingdom. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, a fully digital pain clinic in the United Kingdom. The Company also develops a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company also focuses on developing tetrahydrocannabinol (THC) and cannabinoid (CBD) facilities at this site.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
0139 Field crops, except cash grains, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Executive Director KatharynField 41 2/1/2023 6/24/2022
Chief Financial Officer CharnDeol 56 12/4/2023 12/4/2023
Independent Director ChristopherCooper 53 4/1/2024 4/1/2024
Independent Director JatinderDhaliwal 36 6/24/2022 6/24/2022
Independent Director DavidJenkins 43 2/1/2023 2/1/2023

Business Names
Business Name
1371011 BC Ltd
AKAN
AKANDA CORP.
7 additional Business Names available in full report.

General Information
Number of Employees: 5 (As of 4/29/2024)
Outstanding Shares: 1,297,343 (As of 6/30/2024)
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024